[go: up one dir, main page]

EP2748328A4 - Peg-interferon lambda 1 conjugates - Google Patents

Peg-interferon lambda 1 conjugates

Info

Publication number
EP2748328A4
EP2748328A4 EP12825651.8A EP12825651A EP2748328A4 EP 2748328 A4 EP2748328 A4 EP 2748328A4 EP 12825651 A EP12825651 A EP 12825651A EP 2748328 A4 EP2748328 A4 EP 2748328A4
Authority
EP
European Patent Office
Prior art keywords
conjugates
peg
interferon lambda
interferon
lambda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12825651.8A
Other languages
German (de)
French (fr)
Other versions
EP2748328A1 (en
Inventor
Nhan Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanogen Pharmaceutical Biotechnology
Original Assignee
Nanogen Pharmaceutical Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology filed Critical Nanogen Pharmaceutical Biotechnology
Publication of EP2748328A1 publication Critical patent/EP2748328A1/en
Publication of EP2748328A4 publication Critical patent/EP2748328A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP12825651.8A 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates Withdrawn EP2748328A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN201102222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (2)

Publication Number Publication Date
EP2748328A1 EP2748328A1 (en) 2014-07-02
EP2748328A4 true EP2748328A4 (en) 2015-03-04

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12825651.8A Withdrawn EP2748328A4 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Country Status (9)

Country Link
EP (1) EP2748328A4 (en)
JP (1) JP2014525939A (en)
CN (1) CN103228792A (en)
AU (1) AU2012299423A1 (en)
BR (1) BR112014004302A2 (en)
CA (1) CA2846092A1 (en)
RU (1) RU2014111179A (en)
WO (1) WO2013028233A1 (en)
ZA (1) ZA201401159B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3416675T3 (en) * 2016-02-19 2021-10-11 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda
EP3375452B1 (en) 2017-03-16 2025-01-08 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
RU2678332C1 (en) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
CN112245570A (en) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 An interferon-based treatment for diseases
AU2022209506A1 (en) 2021-01-21 2023-09-07 Biosteed Gene Transformation Tech. Co., Ltd. Method and pharmaceutical combination for preventing cancer recurrence
CN117255695A (en) 2021-01-21 2023-12-19 厦门特宝生物工程股份有限公司 Cancer treatment method and pharmaceutical composition based on interferon
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1176137C (en) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine
CN1927388B (en) * 2004-09-10 2011-02-02 北京金迪克生物技术研究所 Medicinal composition containing human interferon
CN101247821B (en) * 2005-06-03 2013-01-23 Ambrx公司 Improved human interferon molecules and their uses
DK1931704T3 (en) * 2005-10-04 2011-03-14 Zymogenetics L L C Generation and Purification of IL-29
CN101002942B (en) * 2007-01-08 2010-07-21 湖南大学 A kind of PEGylated liposome nanoparticle
CN103536906A (en) * 2008-06-05 2014-01-29 津莫吉尼蒂克斯公司 Use of pegylated Type III Interferons for the treatment of hepatitis C

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHAD ET AL: "Interferon to PEG-Interferon: A Review", THE JOURNAL OFTEACHERS ASSOCIATIONRMC, RAJSHAHI, vol. 17, no. 2, 1 December 2004 (2004-12-01), XP002734715 *
MUIR ANDREW J ET AL: "Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection", HEPATOLOGY, vol. 52, no. 3, September 2010 (2010-09-01), pages 822 - 832, XP002734714, ISSN: 0270-9139 *
See also references of WO2013028233A1 *

Also Published As

Publication number Publication date
EP2748328A1 (en) 2014-07-02
ZA201401159B (en) 2015-04-29
CN103228792A (en) 2013-07-31
BR112014004302A2 (en) 2017-06-20
AU2012299423A1 (en) 2014-03-06
WO2013028233A1 (en) 2013-02-28
CA2846092A1 (en) 2013-02-28
RU2014111179A (en) 2015-09-27
JP2014525939A (en) 2014-10-02

Similar Documents

Publication Publication Date Title
ZA201401159B (en) Peg-interferon lambda 1 conjugates
FR2971446B3 (en) COIFF'RASOIR
GB201121094D0 (en) Concept 58
GB201120424D0 (en) Concept 66
GB201119762D0 (en) Concept 65
GB201117189D0 (en) Concept 64
GB201114556D0 (en) Concept 42
GB201114546D0 (en) Concept 22
GB201114511D0 (en) Concept 7
GB201114478D0 (en) Concept 11
GB201114480D0 (en) Concept 9
GB201114503D0 (en) Concept 54
GB201114486D0 (en) Concept 6
GB201114565D0 (en) Concept 52
GB201114564D0 (en) Concept 51
GB201114563D0 (en) Concept 50
GB201114562D0 (en) Concept 48
GB201114561D0 (en) Concept 47
GB201114560D0 (en) Concept 46
GB201114559D0 (en) Concept 44
GB201114558D0 (en) Concept 43
GB201114517D0 (en) Concept 15
GB201114557D0 (en) Concept 4
GB201114535D0 (en) Concept 38
GB201114550D0 (en) Concept 30

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150203

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 11/00 20060101AFI20150123BHEP

Ipc: C12P 21/04 20060101ALI20150123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151203